BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11297240)

  • 21. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
    Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.
    Lee JS; Murphy WK; Shirinian MH; Pang A; Hong WK
    Cancer Chemother Pharmacol; 1991; 28(3):199-204. PubMed ID: 1649705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial.
    Colon-Otero G; Niedringhaus RD; Hillman SH; Geyer S; Sloan J; Krook JE; Windschitl HE; Marks RS; Wiesenfeld M; Tschetter LK; Jett JJ;
    Am J Clin Oncol; 2001 Dec; 24(6):551-5. PubMed ID: 11801752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin and dichloromethotrexate: a pharmacologically rational combination.
    Natale RB; Wheeler RH; Roberts JA
    NCI Monogr; 1987; (5):219-23. PubMed ID: 3431592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
    Park SH; Gray WC; Hernandez I; Jacobs M; Ord RA; Sutharalingam M; Smith RG; Van Echo DA; Wu S; Conley BA
    Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
    Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
    Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
    Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.
    Perez EA; Hack FM; Webber LM; Chou TC
    Cancer Chemother Pharmacol; 1993; 33(3):245-50. PubMed ID: 8269606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
    Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
    J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
    Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
    Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line.
    Perez EA; Hack FM; Fletcher TS; Chou TC
    Oncol Res; 1994; 6(3):151-6. PubMed ID: 7994086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
    Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
    J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
    Huber MH; Dimery IW; Benner SE; Lippman SM; Shirinian M; Esparaz B; Frenning D; Guillory-Perez C; Hong WK
    Invest New Drugs; 1994; 12(4):327-31. PubMed ID: 7775135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
    Ratliff AF; Wilson J; Hum M; Marling-Cason M; Rose K; Winick N; Kamen BA
    J Clin Oncol; 1998 Apr; 16(4):1458-64. PubMed ID: 9552052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
    Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
    Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
    Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung.
    Varveris H; Kachris S; Mazonakis M; Lyraraki E; Markouizou A; Karabekios S; Tzedakis A; Perisinakis K; Damilakis J; Vlachaki M
    Oncol Rep; 2004 Aug; 12(2):473-81. PubMed ID: 15254718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
    Vandenberg TA; Pritchard KI; Eisenhauer EA; Trudeau ME; Norris BD; Lopez P; Verma SS; Buckman RA; Muldal A
    J Clin Oncol; 1993 Jul; 11(7):1241-4. PubMed ID: 8315420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of metoprine in patients with advanced cancer.
    Currie VE; Kempin SJ; Young CW
    Cancer Treat Rep; 1980; 64(8-9):951-6. PubMed ID: 6969632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.